Search BioPortfolio:
BioPortfolio
Web
Home
Marketing Services
News
Reports
Company Profiles
InDepth
Drug Discovery
Careers
Conferences
Videos
Search
Contact
Items Ordered:
Cart Value:
New Products:
1.
The Rise of Mid-Sized Pharma
2.
Contract Research Annual Review 2008
3.
Amgen - The Biotech Leader - Market Analyses and Outlook, 2008-2023
4.
The World OTC Pharmaceutical Market Analysis and Forecasts, 2008-2023
5.
Monoclonal Antibodies Report: 2008 Update
6.
Pipeline and Commercial Insight: Neuropathic Pain - UCB's Vimpat set to compete with major players
7.
Stakeholder Opinions: Non-hormonal Treatments for Menopausal Symptoms - Market open to takers as tepid pipeline fails to meet demand
8.
Rx-to-OTC Strategies: Maximizing the Commercial Potential of an Rx-to-OTC Switch
9.
Drug Repositioning Strategies - Serendipity by design
10.
Forecast Insight: Osteoarthritis - The COX-2 pipeline collapses
Best Sellers:
1.
BioNewsCast Press Release Distribution Service
2.
Immunogenicity to Biologics Implications of reactions against biotech drugs
3.
Outsourcing in Drug Discovery, 3rd Edition
4.
American Hospital Register
5.
Professional Designation in Biopharmaceutical Technology - 3 Course Curriculum
6.
Outlook for RNAi, 2007 - siRNA and miRNA in biology, diagnostics and therapeutics
Thorcic Aortic Aneurysm and Dissection Endovascular Technology and Market Forecast
An estimated 35,000 thoracic aortic surgical and endovascular interventions are performed every year in the developed world (10,000 in the US alone) at a combined cost to individuals, insurance companies and tax payers of $3.5 billion a year.
40% of these operations are performed on the descending thoracic aorta. Even in the best hands, surgical repair in this anatomical region is difficult and has been associated with devastating complications, especially in those who are not fit for thoracotomy. The endovascular approach can potentially replace these operations.
By the end of 2006 the global market for thoracic aortic stent grafts and access devices was estimated at US$70 million. The fan fair surrounding the approval of the Gore Tag thoracic stent graft system in the US has kicked off the market to a good start.
Based on current technology situation, published company and investment analysts forecasts and feedback from industry executives and thought leaders we forecast the market to reach US$250 million, globally, by 2012.
Thoracic Aortic Aneurysm & Dissection - Endovascular Technology & Market Forecast is a timely new report from Medtech Ventures targeted at busy executives in the medical device and venture capital industries. With the help of this report you will be able to:
" Understand current market dynamics, competitors positions and market shares.
" Assess market size and growth potential for these new devices.
" Monitor the competition's marketed and in-development products
" Identify emerging technologies and the companies behind them
" Assess market potential and have access to forecasts till 2012
" Leverage your own technology and brain storm new business opportunities
" Investigate mergers, acquisitions and licensing possibilities
Date Published: April 2007
Number of Pages: 21
PDF Format
Table of Contents
Price
PDF Single User $780.00
PDF Site Licence $1560.00
Buy Biotechnology Management Reports online with BioPortfolio's secure E-Commerce portal.